Collegium Pharmaceutical's wisdom is in developing over-the-counter and prescription drugs for a variety of conditions affecting the skin and central nervous and respiratory systems. Typically the company starts with existing drugs and works to improve them through new delivery systems that modify their release, or prevent abuse. It is working with drugs to treat such conditions as fibromyalgia, pain, and sleep apnea. Through its subsidiary Onset Therapeutics, the company markets wound care and dermatology (acne, skin infections) drugs. Its topical aerosol product Exactacain is licensed and sold by Healthpoint while its approved allergy nasal spray AllerNaze is licensed to Lupin Ltd.

Kalypsys is searching for new medicines, and has developed a zippy way to find them. Its ultra-high throughput automated epiK screening system can analyze more than one million cell-based assay wells a day and can run 24 hours a day seven days a week. With that kind of research capability, the company has developed its own bioinformatics software to enable researchers to quickly find and compare data points. Kalypsys is generous enough to market the system, under the Kalypsys Systems brand, to other pharmaceutical research facilities. Its own drug development pipeline includes compounds in early stages of development, targeting cancer, inflammatory diseases, pain, and metabolic diseases.

Anacor Pharmaceuticals is a biopharmaceutical company developing novel small-molecule therapeutics derived from its boron chemistry platform to treat infectious and inflammatory diseases. Anacor's most advanced product candidate is AN2690, a novel topical antifungal for the treatment of toenail onychomycosis, a fungal infection of the nail and nail bed. Anacor also has a portfolio of other topical product candidates in development for the treatment of psoriasis, atopic dermatitis and skin and nail fungal infections. The company has entered into a worldwide license, development and commercialization agreement with Merck for the development and commercialization of AN2690 for all indications including the treatment of onychomycosis. In addition, Anacor has a research and development agreement with GSK for novel antiviral and antibacterial systemic therapeutics.

OncoGenex Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for the treatment of cancer. The company's lead candidate, OGX-011, is being evaluated in five Phase II clinical trials. OGX-011, which is also known as custirsen sodium, inhibits the production of clusterin, a protein that is over-produced in various types of cancer and in response to a range of cancer treatments, including hormone ablation therapy, chemotherapy, and radiation therapy. Its other product candidates include OGX-427, a Phase 1 clinical trial product, which is focused on reducing heat shock protein 27; and SN2310, a phase I clinical trial completed product for the treatment of cancer. The company's preclinical stage products consist of OGX-225, an inhibitor of insulin growth factor binding proteins 2 and 5; and CSP-9222, a compound from a family of caspase activators. OncoGenex Pharmaceuticals is based in Bothell, Washington.

Jamieson Laboratories, founded in 1922, manufactures and sells vitamin, multivitamin, and mineral formulations, as well as nutritional food supplements, cosmetics and skin care products, sports nutritionals, home remedy supplements, and diet and digestive formulations. Products may be purchased through health-food, nutrition, and other specialty retailers around Canada. The company also exports its products to approximately 50 countries in the Americas, Asia, Europe, the Middle East, and Africa.

PharmaNet, a global, drug development services company, provides a comprehensive range of services to the pharmaceutical, biotechnology, generic drug, and medical device industries. PharmaNet offers clinical-development solutions including consulting services, Phase I clinical studies, bioequivalency and pharmacodynamic studies, bioanalytical analyses, and Phase II, III, and IV clinical development programs. In addition, PharmaNet offers technology tools for managing clinical trial data.

Spectral Diagnostics Inc. company was founded in 1991 and is based in Toronto, Canada. Spectral Diagnostics Inc. operates in the in vitro diagnostic testing market. The company focuses on the development, manufacture, and sale of diagnostic tests that provide information to physicians. Its products include EAA Endotoxin Activity Assay, a diagnostic test in the field of sepsis; and RapidWN West Nile Virus IgM Test, an assay that helps physicians in obtaining diagnostic information regarding exposure to the West Nile virus. The company also offers other proprietary biochemicals, including monoclonal antibodies and recombinant proteins. Spectral Diagnostics Inc. has operations primarily in Canada, the United States, and Europe.

Trinity Biotech plc was founded in 1992 and is headquartered in Bray, Ireland. Trinity Biotech plc develops, acquires, manufactures, distributes, and sells diagnostic test kits and instrumentation worldwide. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, sexually transmitted diseases, blood coagulation, and autoimmune disorders. It also sells raw materials to the life sciences industry. In addition, the company offers point of care diagnostic tests, which are carried out in the presence of the patient, principally to diagnose the presence of HIV antibodies in the patient. Its customers include hospitals, clinical laboratories, commercial reference laboratories, and research institutions. The company sells its products through distributor partners, as well as directly in the United States, the United Kingdom, France, and Germany.

Dechra lies down with dogs ... and cats and birds and horses too. Dechra Pharmaceuticals lays claim to being the only listed pharmaceutical company that makes most of its income from the animal health care market. The company manufactures and distributes veterinary pharmaceutical products and supplies internationally, mainly in the US and the UK. Its network of subsidiaries includes suppliers National Veterinary Services and Dechra Veterinary Products, manufacturer Dales Pharmaceuticals, and development companies North Western Laboratories and Cambridge Specialist Laboratory Services.

PML Microbiologicals, Inc. company was founded in 1969 and is headquartered in Wilsonville, Oregon. It has manufacturing facilities in Mississauga, Canada; and Portland, Oregon. As of December 8, 2008, PML Microbiologicals, Inc. operates as a subsidiary of BioMérieux S.A. PML Microbiologicals, Inc. manufactures culture media and microbiological products for clinical and industrial applications in North America. It offers prepared culture media, stains, reagents, quality control organisms, sterility products, and collection and transport systems, as well as accessories for microbiology laboratories. The company also provides custom products, such as minimum inhibitory concentration panels, parasitology kits, diluents, and rinsing fluids. It serves clinical, pharmaceutical, research, environmental, personal care, and food and beverage industries. PML Microbiologicals, Inc. was formerly known as Prepared Media Laboratory.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.